Summary
Eli Lilly & Company (LLY) filed an 8-K on April 19, 2010, to report its financial results for the first quarter ended March 31, 2010. The filing highlights the company's use of non-GAAP financial measures to provide a clearer picture of ongoing operational performance, excluding certain significant items. These adjustments are intended to help investors better understand underlying business trends and facilitate meaningful period-over-period comparisons. Key financial adjustments for the first quarter of 2010 included charges related to an in-licensing transaction with Acrux and restructuring costs associated with strategic actions and workforce reductions. For comparison with prior periods, the company also noted adjustments for asset impairments, restructuring charges from strategic actions, and an in-process R&D charge from a licensing agreement with Incyte Corporation. The company also provided financial guidance for 2010, including the estimated impact of U.S. healthcare reform, on both GAAP and non-GAAP bases.
Key Highlights
- 1Announcement of Q1 2010 financial results and a related analyst teleconference and webcast.
- 2Company's utilization of non-GAAP financial measures (e.g., non-GAAP net income, EPS) for enhanced operational performance analysis.
- 3Exclusion of specific items in Q1 2010 non-GAAP results, including in-process R&D charges (Acrux) and restructuring charges.
- 4Presentation of Q1 2010 results with quantification of foreign exchange rate impacts and U.S. healthcare reform effects.
- 5Provision of 2010 financial expectations, including the impact of U.S. healthcare reform on earnings and revenue.
- 6Management's rationale for using non-GAAP measures: evaluating ongoing operations, facilitating comparisons, identifying trends, and internal performance evaluation.
- 7Disclosure that the provided information is furnished and not deemed filed under Section 18 of the Exchange Act.